CClinicalTrials.gg
RecruitingNCT05721378PIONEERUpdated Oct 17, 2024

Permissive Weight Bearing in Displaced Intra-articular Calcaneal Fractures

An interventional study of Permissive Weight Bearing group and Restricted Weight Bearing group in Calcaneus Fracture, Displaced Intra-Articular Fracture of Calcaneus (Diagnosis) and Trauma Injury, sponsored by Maastricht University Medical Center. Recruiting at 11 sites in Netherlands. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 67 Years
Sex
All
01

Study summary

The goal of the proposed study is to define the optimal rehabilitation for trauma patients with Displaced Intra-articular Calcaneal Fractures, either Permissive Weight Bearing (PWB) or Restricted Weight Bearing (RWB) regarding functional outcomes, health related quality of life, radiographical differences, cost-effectiveness and complications.

Read the detailed description

Rationale: Of all fractures, 1-2% involve the calcaneus. Often surgical treatment is needed. Even after successful treatment it requires long rehabilitation with major impact on daily life and socio-economic aspects. Anatomic surgical restoration does not prevent gait disturbances or persistent foot pain. An adequate rehabilitation program is mandatory to maximize foot stability.

Objective: Evidence showing which rehabilitation protocol is best for both fracture healing and quality of life for patients with Displaced Intra-Articular Calcaneal Fractures (DIACFs) is mostly lacking. This study has the aim to answer the question whether surgically treated patients with DIACFs following the Permissive Weight Bearing protocol (PWB) have better functional outcomes compared to patients with Restricted Weight Bearing protocol after 12 weeks (RWB) measured with the American Orthopaedic Foot \& Ankle Society (AOFAS) Score. The study hypothesizes that patients with DIACFs following the PWB protocol will have a better quality of life (HR-QOL) compared to patients who followed the RWB protocol.

The hypothesis is that there will be lower costs without any radiographic differences for surgically treated (irrespective of technique used) patients with DIACFs following a PWB protocol comparing to the current AO (Arbeitsgemeinschaft für Osteosynthesefragen) standard care: the RWB protocol.

Study design: Multi-center randomized controlled trial

Study population: Presence of surgically (extended lateral, sinus tarsi or percutaneous approach) fixed DIACFs classified as Sanders type II to IV, age 18-67 years (labor force). Patients must be able to understand and follow weight bearing instructions. Patients will only be included after written informed consent is obtained.

Groups (intervention and control): Patients with DIACFs will be randomly allocated to one of the rehabilitation protocols, either PWB or RWB.

Main study parameters/endpoints: Primary objective: functional outcome. Secondary outcomes: quality of life, differences in radiographic parameters, complications, cost effectiveness and differences in surgical techniques.

Nature and extent of the burden: The PWB protocol aims to restore weight bearing faster than RWB protocol in DIACFs. Early postoperative weight bearing poses the risk of increased complications, such as secondary displacement of the fracture or failure of fracture fixation. Previous analysis of this protocol in other lower extremity fractures has shown a safe complication rate, although data from prospective randomized trials in calcaneus fractures are lacking. Follow-up is standardized according to current trauma guidelines, namely at time points 2, 6, 12 weeks and 6 months. The radiation exposure will not be different from standard of care. Therefore, the burden for participants is considered minimal, with no significant health risks.

02

Conditions studied

  • Calcaneus Fracture
  • Displaced Intra-Articular Fracture of Calcaneus (Diagnosis)
  • Trauma Injury

Browse trials for

Keywords

  • Permissive Weight Bearing
  • Rehabilitation
03

In context

Fractures, Bone

2,261 studies on the registry are indexed under Fractures, Bone; 325 are open to participants now.

This study's planned enrollment of 115 is above the median of 69 across 1,482 interventional studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 835 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Surgically treated trauma patients with isolated unilateral DIACFs, less than 6 weeks after trauma, Sanders type II-IV (14)
  • Age between 18 and 67 years old (labor force)
  • Being able to understand the questionnaires and measurement instructions
  • Indication for open/closed reduction and internal fixation
  • Written Informed Consent

Exclusion criteria

Exclusion Criteria:

  • Acute or existing amputation (upper limb, lower limb, feet)
  • Open calcaneal fractures (excluding medial wound without compromising surgical approach)
  • Bilateral fractures of the lower extremities
  • Unable to comply to the PWB protocol due to pre-existing conditions of the arms and legs (e.g. unable to use crotches due to hemiparalysis)
  • Severe non-fracture related comorbidity of the lower extremity
  • Pre-existent immobility (loss of muscle function of one or both legs)
  • Dependent in activities of daily living (e.g. due to dementia, Alzheimer, New York Heart Association class IV angina, heart failure or oxygen-dependent chronic obstructive pulmonary disease)
  • Rheumatoid arthritis of the lower extremities
  • Severe psychiatric comorbidities that lead to inability to comply with the treatment protocol
  • Pathologic fractures (metastasis, secondary osteoporosis)
  • Peripheral neuropathy and/or diabetes
  • Alcohol- or drug abuse preventing adequate follow-up
  • Primary indication for arthrodesis subtalar joint
  • Two or more fractures of the upper and/or lower extremities
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Permissive Weight Bearing group

    Rehabilitation following the Permissive Weight Bearing (PWB) protocol

    Procedure: Permissive Weight Bearing group

  • Active comparator
    Restrictive Weight Bearing group

    Rehabilitation following the Restrictive Weight Bearing (RWB) protocol

    Procedure: Restricted Weight Bearing group

Interventions

  • ProcedurePermissive Weight Bearing group

    The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.

    Also known as: Early Weight Bearing

  • ProcedureRestricted Weight Bearing group

    The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.

    Also known as: Non Weight Bearing

06

What researchers measure

Primary outcomes

  1. Change in functional outcome as defined by the AOFAS questionnaire

    The American Orthopaedic Foot \& Ankle Society (AOFAS) score is a clinician-based score. It incorporates both subjective and objective information. Patients report their pain, and physicians assess alignment. It is designed for physicians to help standardize the assessment of patients and makes the results of this study comparable with previous data. Scores range from 0 to 100, with healthy foot and ankles receiving 100 points.

    Time frame: 0, 2, 6, 12 weeks and 6 months post-surgery.

Secondary outcomes

  1. Self-reported function with the Maryland Foot Score

    The MFS is an assessment for foot disorders, mainly consisting of the following items: pain, gait, functional activities, and cosmesis. The scale scores have a minimum of 0 points and a maximum of 100 points. A total score of \<50 is considered as poor, 50-74 as fair, 75-89 as good, and 90-100 as excellent.

    Time frame: 0, 2, 6, 12 weeks and 6 months post-surgery

  2. Activities of Daily Living (ADL) with LEFS

    The lower extremity functional scale (LEFS) is a questionnaire containing 20 questions about a person's ability to perform everyday tasks. The LEFS can be used by clinicians as a measure of patients' initial function, ongoing progress, and outcome, as well as to set functional goals. The LEFS can be used to evaluate the functional impairment of a patient with a disorder of one or both lower extremities. It can be used to monitor the patient over time and to evaluate the effectiveness of an intervention. The questionnaire consists of 80 points. The lower the score the greater the disability.

    Time frame: 0, 2, 6, 12 weeks and 6 months post-surgery

  3. Health Related Quality of Life with EQ-5D-5L

    The EuroQol 5-Dimension, 5-Level Health Scale (EQ-5D-5L) is a self-administered questionnaire, which will be completed at baseline together with the cost questionnaire at the same moments (0, 2, 6, 12 weeks and 6 months). Both generic quality of life, as well as utilities, will be derived by means of the EQ-5D-5L, which will be administered both by the patients. The Dutch version of the EQ-5D-5L is chosen because it is a widely used quality of life instrument (nationally and internationally) and it is recommended by the Dutch guidelines.The EQ-5D-5L contains 5 dimensions of health-related quality of life, namely mobility, self-care, daily activities, pain/discomfort and depression/anxiety. Each dimension can be rated at five levels: no problems to major problems. The 5 dimensions can be summed into a health state.

    Time frame: 0, 2, 6, 12 weeks and 6 months post-surgery

  4. Böhlers angle and posterior facet joint

    Radiographic evaluation by a radiologist blinded for treatment allocation will be done at the same time intervals as the scheduled visits to the physician. To see if there is a difference in the alignment of Böhlers angle and posterior facet joint alignment (radiographically measured), a CT-scan will be performed early post-operatively (before first weight bearing) and after 6 months. Differences in the Böhlers angle and posterior joint alignment (Δ = CT6months - CTpost-op.) will be calculated. The normal degree for the Böhler angle varieties between 25° and 40°. An intra-articular step off or gap from less than 2mm of the posterior facet was considered as well-reduced.

    Time frame: Early postoperative (before first mobilization) and 6 months post-surgery

  5. Medical consumption with iMCQ

    The iMTA Medical Consumption Questionnaire (iMCQ) measures health care utilization and is based on 29 questions. It is an instrument for measuring medical consumption and is related to frequently occurring contacts with health care providers. The iMCQ is a generic questionnaire. It is therefore not disease specific. The questions ask about health care related appointments patients had in the past period. In case the respondent had no appointments, the score '0' is noted.

    Time frame: 0 weeks and 6 months post-surgery

  6. Society costs with iPCQ

    The iMTA Productivity Cost Questionnaire (iPCQ) measures productivity losses. The questionnaire is based on 12 questions. Questions 1 to 3 give information about the amount of paid work (in hours) and the number of days per week on which the respondent works. The latter provides insight into the average number of hours of work per working day of the respondent. This information is needed to calculate productivity loss costs. The questions about productivity losses form the following modules: * Absenteeism: absenteeism from paid work (questions 4 to 6) * Presenteeism: productivity losses during days worked (questions 7 to 9) * Productivity loss from unpaid work (questions 10 to 12). After completing the questionnaire the total amount of absenteeism can be calculated by multiplying the number of days absent and the number of hours per working day of the respondent. To calculate the costs of productivity losses, volumes are multiplied by unit cost prices.

    Time frame: 0 weeks and 6 months post-surgery

  7. Occurrence of complications

    Most important complications, such as: wound infection, dislocation, non-union, - failure of osteosynthesis, postoperative arthritis

    Time frame: 6 and 12 weeks and 6 months post-surgery

07

Study locations

2 of 11 sites recruiting
  • Amsterdam University Medical Center
    Amsterdam, Netherlands
    • Tim Schepers · Contact · MD
    Not yet recruiting
  • Rijnstate Hospital
    Arnhem, Netherlands
    • Albert Pull ter Gunne, MD · Contact
    Not yet recruiting
  • Amphia Hospital
    Breda, Netherlands
    • Niels Berende, MD · Contact
    Not yet recruiting
  • Haaglanden Medical Center
    Den Haag, Netherlands
    • Jochem Hoogendoorn, MD · Contact
    Not yet recruiting
  • Catharina Hospital
    Eindhoven, Netherlands
    • Alexander van der Veen, MD · Contact
    Not yet recruiting
  • Groene Hart Hospital
    Gouda, Netherlands
    • Jan Siert Reinders, MD · Contact
    Not yet recruiting
  • Maastricht University Medical Center +
    Maastricht, Netherlands
    • Martijn Poeze, Prof. · Contact
    Recruiting
  • Radboud University Medical Center
    Nijmegen, Netherlands
    • Erik Hermans, MD · Contact
    Recruiting
  • Maasstad Hospital
    Rotterdam, Netherlands
    • Kees van der Vlies, MD · Contact
    Not yet recruiting
  • Zuyderland Medical Center
    Sittard, Netherlands
    • Raoul van Vugt, MD · Contact
    Not yet recruiting
  • Elisabeth-Twee Steden Hospital
    Tilburg, Netherlands
    • Hilco Theeuwes, MD · Contact
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05721378
Lead sponsor
Maastricht University Medical Center
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Jul 1, 2024
Primary completion
Jul 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Oct 17, 2024

Study contacts

Coen Verstappen, MD
Contact
coen.verstappen@mumc.nl
+31(0)43-3877489

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion